Skip to main content

Table 1 The summarized characteristics of patients

From: NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome

Disease FAB type Number of patients (F/M) Age median (range) WBC mean (range) NPM1mut. FLT3mut. RUNX1/RUNX1T1 Karyotype
ddPCR-based analysis of NPM1 transcripts at the time of diagnosis
 AML M0 1 (0/1) 64 9.7 NA (1)
M1 13 (7/6) 51 (25–65) 94.8 (1–310.9) 5 2 Aberrant (3)
NA (10)
M2 23 (8/15) 51 (19–64) 44.8 (0.5–146.4) 5 3 4 Normal (4)
Aberrant (10)
NA (41)
M3 3 (1/2) 60 (54–67) 24.8 (7.2–49.1) 1 1 Aberrant (2)
NA (1)
M4 13 (4/9) 52 (38–75) 51.8 (1.9–165.2) 3 2 Aberrant (2)
NA (11)
M5 4 (3/1) 40 (18–57) 85.6 (35.1–116) 1 1 Aberrant (1)
NA (3)
 ALL ALL-B 8 (3/5) 42.5 (18–57) 17.9 (2.1–68.4) Aberrant (3)
NA (5)
 AML/ALL   1 (1/0) 55 16.4 Aberrant (1)
 All patients   66 (27/39) 50 (18–75) 36.4 (0.5–310.9) 15 (10 exclusive) 9 (4 exclusive) 6 (4 exclusive) Normal (4)
Aberrant (22)
NA (40)
RNA-seq-based analysis of NPM1 transcripts
 AML-T0 M1 9 (6/3) 52 (25–65) 65.1 (14.6–233) 4 1 Normal (1)
Aberrant (3)
NA (5)
M2 18 (7/11) 51.5 (19–64) 37.5 (1.34–146.4) 3 3 3 Aberrant (10)
NA (8)
 AML-T1 M2 1 (0/1) 64 21.7 NA (1)
ddPCR-based analysis of NPM1 transcripts at the three time points
 AML-T0 M1 (3), M2 (6) 9 (3/6) 52 (19–64) 59.9 (11–129.2) 2 2 2 Aberrant (5)
NA (4)
 AML-T1 M1 (1), M2 (8) 9 (3/6) 56 (20–64) 17.9 (2.3–35.4) NA (9)
 AML-T2 M1 (3), M2 (4) 7 (4/3) 54 (20–65) 15.9 (6.6–29.9) 2 1 NA (7)
  1. FLT3 mut. FLT3-ITD (internal tandem duplication in the FLT3 gene), RUNX1/RUNX1T fusion gene, result of t(8;21) translocation, NA data not available, AML-T0 AML at the time of first diagnosis, AML-T1 AML after therapy, AML-T2 AML at the relapse